149 related articles for article (PubMed ID: 12515872)
1. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.
Dizendorf EV; Baumert BG; von Schulthess GK; Lütolf UM; Steinert HC
J Nucl Med; 2003 Jan; 44(1):24-9. PubMed ID: 12515872
[TBL] [Abstract][Full Text] [Related]
2. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
[TBL] [Abstract][Full Text] [Related]
3. [The impact of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) on planning of radiotherapy].
Dizendorf E; Baumert B; von Schulthess GK; Luetolf UM; Steinert HC
Ter Arkh; 2001; 73(10):11-4. PubMed ID: 11763507
[TBL] [Abstract][Full Text] [Related]
4. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
5. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
6. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.
Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY
J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151
[TBL] [Abstract][Full Text] [Related]
7. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
9. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
10. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma.
Yen RF; Hong RL; Tzen KY; Pan MH; Chen TH
J Nucl Med; 2005 May; 46(5):770-4. PubMed ID: 15872349
[TBL] [Abstract][Full Text] [Related]
11. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.
Schöder H; Meta J; Yap C; Ariannejad M; Rao J; Phelps ME; Valk PE; Sayre J; Czernin J
J Nucl Med; 2001 Aug; 42(8):1139-43. PubMed ID: 11483671
[TBL] [Abstract][Full Text] [Related]
12. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.
Antoch G; Vogt FM; Freudenberg LS; Nazaradeh F; Goehde SC; Barkhausen J; Dahmen G; Bockisch A; Debatin JF; Ruehm SG
JAMA; 2003 Dec; 290(24):3199-206. PubMed ID: 14693872
[TBL] [Abstract][Full Text] [Related]
13. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective.
Yap CS; Seltzer MA; Schiepers C; Gambhir SS; Rao J; Phelps ME; Valk PE; Czernin J
J Nucl Med; 2001 Sep; 42(9):1334-7. PubMed ID: 11535721
[TBL] [Abstract][Full Text] [Related]
14. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
[TBL] [Abstract][Full Text] [Related]
15. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
17. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
18. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
20. [Positron emission tomography for the preoperative staging of esophageal carcinoma].
Junginger T; Kneist W; Schreckenberger M; Menzel C; Oberholzer K; Bartenstein P
Dtsch Med Wochenschr; 2002 Sep; 127(38):1935-41. PubMed ID: 12239652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
